15.52
-0.131(-0.84%)
Currency In USD
| Previous Close | 15.65 |
| Open | 15.34 |
| Day High | 15.84 |
| Day Low | 15.05 |
| 52-Week High | 26.99 |
| 52-Week Low | 12.62 |
| Volume | 2,709 |
| Average Volume | 4,508 |
| Market Cap | 40.62M |
| PE | -5.31 |
| EPS | -2.92 |
| Moving Average 50 Days | 15.69 |
| Moving Average 200 Days | 16.65 |
| Change | -0.13 |
If you invested $1000 in vTv Therapeutics Inc. (VTVT) 10 years ago, it would be worth $38.72 as of August 18, 2025 at a share price of $15.519. Whereas If you bought $1000 worth of vTv Therapeutics Inc. (VTVT) shares 5 years ago, it would be worth $165.1 as of August 18, 2025 at a share price of $15.519.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin
GlobeNewswire Inc.
Aug 11, 2025 12:00 PM GMT
HIGH POINT, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being invest
vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes
GlobeNewswire Inc.
Aug 07, 2025 12:00 PM GMT
Topline results from CATT1 Phase 3 trial expected in second half of 2026HIGH POINT, N.C., Aug. 07, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company with an innovative clinical portfolio of small
vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series
GlobeNewswire Inc.
Jun 11, 2025 12:00 PM GMT
HIGH POINT, N.C., June 11, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being in